Q-omics provides the consensus-scored HOXD10 profile across patient tissues and cancer cell-line models. HOXD10 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HOXD10 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, HOXD10 RNA expression shows 13,474 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, HNSC, and TGCT as cancer lineages where HOXD10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXD10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXD10 survival associations across molecular data types. HOXD10 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXD10 RNA expression–survival associations across cancer types. High HOXD10 expression shows unfavorable associations in KIRP, LIHC, LGG, STAD and THCA, but favorable associations in ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HOXD10 RNA expression.
This table summarizes HOXD10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HOXD10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXD10 shows lower tumor expression in KIRC, KICH, KIRP and COAD and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher HOXD10 RNA expression in tumor versus normal tissue (log2 FC = +2.588, t-test p < 0.001).
This table shows molecular features associated with HOXD10 in patient tissues and cancer cell lines. In patient samples, HOXD10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXD10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
